A comprehensive review by researchers at the Institute of Process Engineering illuminates the extensive role of Fusobacterium nucleatum in colorectal cancer development. The bacterium's ability to promote tumor growth and therapy resistance has prompted exploration of antimicrobial and nanomedicine strategies to target it, aiming to enhance treatment outcomes while overcoming challenges like microbiota disruption.